The C‐PLAN index, which combines CRP, PS, LDH, Alb, and derived NLR, may be a useful biomarker that reflects the prognosis of patients with advanced NSCLC who received combination immunotherapy. This evidence concerns the gene ALB and non-small cell lung carcinoma.